Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCMP's 30-Y Financials

Financials (Next Earnings Date: 2018-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

SCMP Guru Trades in Q2 2017

Chuck Royce 1,067,923 sh (+9.64%)
Jim Simons 810,600 sh (-27.06%)
Joel Greenblatt 85,967 sh (-60.91%)
Paul Tudor Jones 16,586 sh (-75.53%)
» More
Q3 2017

SCMP Guru Trades in Q3 2017

Steven Cohen 1,863,435 sh (New)
Jim Simons 1,305,700 sh (+61.08%)
Chuck Royce 1,171,731 sh (+9.72%)
Paul Tudor Jones Sold Out
Joel Greenblatt 39,830 sh (-53.67%)
» More
Q4 2017

SCMP Guru Trades in Q4 2017

Mario Gabelli 29,400 sh (New)
John Paulson 1,600,000 sh (New)
Pioneer Investments 22,000 sh (New)
Jim Simons 1,957,600 sh (+49.93%)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Chuck Royce 879,841 sh (-24.91%)
» More
Q1 2018

SCMP Guru Trades in Q1 2018

Pioneer Investments Sold Out
John Paulson Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2018-03-31 Sold Out $17.85 - $18.6 $ 18.00-0%0
John Paulson 2018-03-31 Sold Out 0.56%$17.85 - $18.6 $ 18.00-0%0
John Paulson 2017-12-31 New Buy0.56%$9.5 - $18 $ 18.0046%1,600,000
Mario Gabelli 2017-12-31 New Buy$9.5 - $18 $ 18.0046%29,400
Joel Greenblatt 2017-12-31 Sold Out 0.01%$9.5 - $18 $ 18.0046%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OSTO:BIOG B, TPE:1789, NSE:STAR, SZSE:002880, XKRX:065660, SZSE:300584, ISX:SIDO, TSX:GUD, SZSE:002365, NAS:ADMS, SHSE:603669, BOM:540222, XKRX:170900, SZSE:002864, NAS:EGRX, NAS:AMPH, NAS:OPTN, NAS:COLL, ISX:KAEF, XKRX:243070 » details
Traded in other countries:R3A.Germany,
Headquarter Location:USA
Sucampo Pharmaceuticals Inc is a pharmaceutical company having its primary market in the United States. It generates revenue from the sale of drugs for the treatment of gastrointestinal diseases.

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $250.47
EPS (TTM) $ -3.28
52-Week Range $9.30 - 18.75
Shares Outstanding (Mil)47.17

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 253 264 307 374
EBIT (Mil $) 115 109 147
EBITDA (Mil $) 115 109 148
EPS ($) -2.79 1.13 1.50 1.58
EPS without NRI ($) -2.79 1.13 1.50 1.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}